The epidermal growth factor receptor as a therapeutic target in epithelial ovarian cancer

Cancer Epidemiology

Volumn 36, Issue 5, 2012, Pages 490-496

  Gui, Ting ^a   Shen, Keng ^a  

^a PEKING UNION MEDICAL COLLEGE HOSPITAL   (China)

Author keywords

Epidermal growth factor receptor (EGFR); Epithelial ovarian cancer (EOC); Monoclonal antibody (MAb); Resistance; Tyrosine kinase inhibitor (TKI)

Indexed keywords

CARBOPLATIN; CETUXIMAB; EPIDERMAL GROWTH FACTOR RECEPTOR; EPIDERMAL GROWTH FACTOR RECEPTOR ANTIBODY; ERLOTINIB; GEFITINIB; PACLITAXEL; PANITUMUMAB; PROTEIN TYROSINE KINASE INHIBITOR;

ANGIOGENESIS; CANCER COMBINATION CHEMOTHERAPY; CANCER INVASION; CELL MIGRATION; CELL PROLIFERATION; EPITHELIAL OVARIAN CARCINOMA; HUMAN; MONOTHERAPY; MULTIPLE CYCLE TREATMENT; NONHUMAN; OVARY CARCINOMA; PRIORITY JOURNAL; PROTEIN FUNCTION; REVIEW;

ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARBOPLATIN; DRUG RESISTANCE, NEOPLASM; ENZYME ACTIVATION; FEMALE; HUMANS; MOLECULAR TARGETED THERAPY; MUTATION; NEOPLASMS, GLANDULAR AND EPITHELIAL; OVARIAN NEOPLASMS; PROTEIN-TYROSINE KINASES; QUINAZOLINES; RECEPTOR, EPIDERMAL GROWTH FACTOR;

EID: 84865860686     PISSN: 18777821     EISSN: 1877783X     Source Type: Journal    
DOI: 10.1016/j.canep.2012.06.005     Document Type: Review

References (82)

1. Onda T., Yoshikawa H. Neoadjuvant chemotherapy for advanced ovarian cancer: overview of outcomes and unanswered questions. Expert Rev Anticancer Ther 2011, 11:1053-1067.
2. Aaronson S.A. Growth factors and cancer. Science 1991, 254:1146-1153.
3. Miettinen P.J., Berger J.E., Meneses J., Phung Y., Pedersen R.A., Werb Z., et al. Epithelial immaturity and multiorgan failure in mice lacking epidermal growth factor receptor. Nature 1995, 376:337-341.
4. Sibilia M., Wagner E.F. Strain-dependent epithelial defects in mice lacking the EGF receptor. Science 1995, 269:234-238.
5. Sibilia M., Kroismayr R., Lichtenberger B.M., Natarajan A., Hecking M., Holcmann M. The epidermal growth factor receptor: from development to tumorigenesis. Differentiation 2007, 75(9):770-787.
6. Yarden Y., The EGFR family and its ligands in human cancer, signalling mechanisms and therapeutic opportunities. Eur J Cancer 2001, 37:S3-S8.
7. Moscatello D.K., Holgado-Madruga M., Godwin A.K., Ramirez G., Gunn G., Zoltick P.W., et al. Frequent expression of a mutant epidermal growth factor receptor in multiple human tumors. Cancer Res 1995, 55(23):5536-5539.
8. Bartlett J.M., Langdon S.P., Simpson B.J., Stewart M., Katsaros D., Sismondi P., et al. The prognostic value of epidermal growth factor receptor mRNA expression in primary ovarian cancer. Br J Cancer 1996, 73(3):301-306.
9. Fischer-Colbrie J., Witt A., Heinzl H., Speiser P., Czerwenka K., Sevelda P., et al. EGFR and steroid receptors in ovarian carcinoma: comparison with prognostic parameters and outcome of patients. Anticancer Res 1997, 17(1B):613-619.
10. Skirnisdottir I., Sorbe B., Seidal T. The growth factors HER-2/neu and EGFR, their relationship, and their effects on the prognosis in early stage (FIGO I-II) epithelial ovarian carcinoma. Int J Gynecol Cancer 2001, 11(2):119-129.
11. Alper O., Bergmann-Leitner E.S., Bennett T.A., Hacker N.F., Stromberg K., Stetler-Stevenson W.G. Epidermal growth factor receptor signaling and the invasive phenotype of ovarian carcinoma cells. J Natl Cancer Inst 2001, 93(18):1375-1384.
12. Tsujioka H., Yotsumoto F., Shirota K., Horiuchi S., Yoshizato T., Kuroki M., et al. Emerging strategies for ErbB ligand-based targeted therapy for cancer. Anticancer Res 2010, 30(8):3107-3112.
13. Ciardiello F., Tortora G. A novel approach in the treatment of cancer: targeting the epidermal growth factor receptor. Clin Cancer Res 2001, 7(10):2958-2970.
14. Arteaga C.L. Overview of epidermal growth factor receptor biology and its role as a therapeutic target in human neoplasia. Semin Oncol 2002, 29:3-9.
15. Arteaga C.L. The epidermal growth factor receptor: from mutant oncogene in nonhuman cancers to therapeutic target in human neoplasia. J Clin Oncol 2001, 19:32s-40s.
16. Nicholson R.I., Gee J.M., Harper M.E. EGFR and cancer prognosis. Eur J Cancer 2001, 37:S9-S15.
17. Berchuck A., Rodriguez G.C., Kamel A., Dodge R.K., Soper J.T., Clarke-Pearson D.L., et al. Epidermal growth factor receptor expression in normal ovarian epithelium and ovarian cancer. I. Correlation of receptor expression with prognostic factors in patients with ovarian cancer. Am J Obstet Gynecol 1991, 164(2):669-674.
18. Yarden Y., Sliwkowski M.X. Untangling the ErbB signalling network. Nat Rev Mol Cell Biol 2001, 2(2):127-137.
19. Lemmon M.A., Schlessinger J. Regulation of signal transduction and signal diversity by receptor oligomerization. Trends Biochem Sci 1994, 19(11):459-463.
20. Arteaga C. Targeting HER1/EGFR: a molecular approach to cancer therapy. Semin Oncol 2003, 30:3-14.
21. Buettner R., Mora L.B., Jove R. Activated STAT signaling in human tumors provides novel molecular targets for therapeutic intervention. Clin Cancer Res 2002, 8(4):945-954.
22. Citri A., Yarden Y. EGF-ERBB signalling: towards the systems level. Nat Rev Mol Cell Biol 2006, 7(7):505-516.
23. Ullrich A., Coussens L., Hayflick J.S., Dull T.J., Gray A., Tam A.W., et al. Human epidermal growth factor receptor cDNA sequence and aberrant expression of the amplified gene in A431 epidermal carcinoma cells. Nature 1984, 309(5968):418-425.
24. Pedersen M.W., Meltorn M., Damstrup L., Poulsen H.S. The type III epidermal growth factor receptor mutation, biological significance and potential target for anti-cancer therapy. Ann Oncol 2001, 12(6):745-760.
25. Chu C.T., Everiss K.D., Wikstrand C.J., Batra S.K., Kung H.J., Bigner D.D. Receptor dimerization is not a factor in the signalling activity of a transforming variant epidermal growth factor receptor (EGFRvIII). Biochem J 1997, 324:855-861.
26. Moscatello D.K., Holgado-Madruga M., Godwin A.K., Ramirez G., Gunn G., Zoltick P.W., et al. Frequent expression of a mutant epidermal growth factor receptor in multiple human tumors. Cancer Rex 1995, 55(23):5536-5539.
27. Lassus H., Sihto H., Leminen A., Joensuu H., Isola J., Nupponen N.N., et al. Gene amplification, mutation and protein expression of EGFR and mutations of ERBB2 in serous ovarian carcinoma. J Mol Med (Berl) 2006, 84(8):671-681.
28. Steffensen K.D., Waldstrom M., Olsen D.A., Corydon T., Lorentzen K.A., Knudsen H.J., et al. Mutant epidermal growth factor receptor in benign, borderline, and malignant ovarian tumors. Clin Cancer Res 2008, 14(11):3278-3282.
29. Salomon D.S., Brandt R., Ciardiello F., Normanno N. Epidermal growth factor-related peptides and their receptors in human malignancies. Crit Rev Oncol Hematol 1995, 19(3):183-232.
30. Fan Z., Baselga J., Masui H., Mendelsohn J. Antitumor effect of anti-epidermal growth factor receptor monoclonal antibodies plus cis-diamminedichloroplatinum on well established A431 cell xenografts. Cancer Res 1993, 53(19):4637-4642.
31. Karnes W.E., Weller S.G., Adjei P.N., Kottke T.J., Glenn K.S., Gores G.J., et al. Inhibition of epidermal growth factor receptor kinase induces protease-dependent apoptosis in human colon cancer cells. Gastroenterology 1998, 114(5):930-939.
32. Zandi R., Larsen A.B., Andersen P., Stockhausen M.T., Poulsen H.S. Mechanisms for oncogenic activation of the epidermal growth factor receptor. Cell Signal 2007, 19(10):2013-2023.
33. Jonker D.J., O'Callaghan C.J., Karapetis C.S., Zalcberg J.R., Tu D., Au H.J., et al. Cetuximab for the treatment of colorectal cancer. N Engl J Med 2007, 357(20):2040-2048.
34. Bull Phelps S.L., Schorge J.O., Peyton M.J., Shigematsu H., Xiang L.L., Miller D.S., et al. Implications of EGFR inhibition in ovarian cancer cell proliferation. Gynecol Oncol 2008, 109(3):411-417.
35. Perrotte P., Matsumoto T., Inoue K., Kuniyasu H., Eve B.Y., Hicklin D.J., et al. Anti-epidermal growth factor receptor antibody C225 inhibits angiogenesis in human transitional cell carcinoma growing orthotopically in nude mice. Clin Cancer Res 1999, 5(2):257-265.
36. Schilder R.J., Pathak H.B., Lokshin A.E., Holloway R.W., Alvarez R.D., Aghajanian C., et al. Phase II trial of single agent cetuximab in patients with persistent or recurrent epithelial ovarian or primary peritoneal carcinoam with the potential for dose escalation to rash. Gynecol Oncol 2009, 113(1):21-27.
37. Secord A.A., Blessing J.A., Armstrong D.K., Rodgers W.H., Miner Z., Barnes M.N., et al. Phase II trial of cetuximab and carboplatin in relapsed platinum-sensitive ovarian cancer and evaluation of epidermal growth factor receptor expression: a Gynecologic Oncology Group study. Gynecol Oncol 2008, 108(3):493-499.
38. Harding J., Burtness B. Cetuximab: an epidermal growth factor receptor chemeric human-murine monoclonal antibody. Drugs Today (Barc) 2005, 41(2):107-127.
39. Wu M., Rivkin A., Pham T. Panitumumab: human monoclonal antibody epidermal growth factor receptors for the treatment of metastatic colorectal cancer. Clin Ther 2008, 30(1):14-30.
40. Yang X., Jia X.C., Corvalan J.R., Wang P., Davis C.G. Development of ABX-EGF, a fully human anti-EGF receptor monnoclonal antibody, for cancer therapy. Crit Rev Oncol Hematol 2001, 38(1):17-23.
41. Ciardiello F., Tortora G. EGFR antagonists in cancer treatment. N Engl J Med 2008, 358(11):1160-1174.
42. Kumar A., Petri E.T., Halmos B., Boggon T.J. Structure and clinical relevance of the epidermal growth factor receptor in human cancer. J Clin Oncol 2008, 26(10):1742-1751.
43. Klausz K., Berger S., Lammerts van Bueren J.J., Derer S., Lohse S., Dechant M., et al. Complement-mediated tumor-specific cell lysis by antibody combinations targeting epidermal growth factor receptor (EGFR) and its variant III (EGFRvIII). Cancer Sci 2011, 102(10):1761-1768.
44. Lorimer I.A. Mutant epidermal growth factor receptors as targets for cancer therapy. Curr Cancer Drug Targets 2002, 2(2):91-102.
45. Hidalgo M., Sui L.L., Nemunaitis J., Rizzo J., Hammond L.A., Takimomto C., et al. Phase I and pharmacokinetic study of OSI-774, an epidermal growth factor receptor tyrosine kinase inhibitor, in patients with advanced solid malignancies. J Clin Oncol 2001, 19(13):3267-3279.
46. Dai Q., Ling Y.H., Lia M., Zou Y.Y., Kroog G., Iwata K.K., et al. Enhanced sensitivity to the HER1/epidermal growth factor receptor tyrosine kinase inhibitor erlotinib hydrochloride in chemotherapy-resistant tumor cell lines. Clin Cancer Res 2005, 11(4):1572-1578.
47. Gordon A.N., Finkler N., Edwards R.P., Garcia A.A., Crozier M., Irwin D.H., et al. Efficacy and safety of erlotinib HCL, an epidermal growth factor receptor (HER1/EGFR) tyrosine kinase inhibitor, in patients with advanced ovarian carcinoma: results from a phase II multicenter study. Int J Gynecol Cancer 2005, 15(5):785-792.
48. Blank S.V., Christos P., Curtin J.P., Goldman N., Runowicz C.D., Sparano J.A., et al. Erlotinib added to carboplatin and paclitaxel as first-line treatment of ovarian cancer: a phase II study based on surgical reassessment. Gynecol Oncol 2010, 119(3):451-456.
49. Vasey P.A., Gore M., Wilson R., Rustin G., Gabra H., Guastalla J.P., et al. A phase Ib trial of docetaxel, carboplatin and erlotinib in ovarian, fallopian tube and primary peritoneal cancers. Br J Cancer 2008, 98(11):1774-1780.
50. Hirte H., Oza A., Swenerton K., Ellard S.L., Grimshaw R., Fisher B., et al. A phase II study of erlotinib (OSI-774) given in combination with carboplatin in patients with recurrent epithelial ovarian cancer. Gynecol Oncol 2010, 118(3):308-312.
51. Ranson M., Hammond L.A., Ferry D., Kris M., Tullo A., Murray P.I., et al. ZD 1839, a selective oral epidermal growth factor receptor tyrosine kinase inhibitor, is well tolerated and active in patients with solid, malignant tumors: results of a phase I trial. J Clin Oncol 2002, 20(9):2240-2250.
52. Smith J.A., Gaikwad A., Yu J., Wolf J.K., Brown J., Ramondetta L.M., et al. In vitro evaluation of the effects of gefitinib on the modulation of cytotoxic activity of selected anticancer agents in a panel of human ovarian cancer cell lines. Cancer Chemother Pharmocol 2008, 62(1):51-58.
53. Schilder R.J., Sill M.W., Chen X., Darcy K.M., Decesara S.L., Lewandowski G., et al. Phase II study of gefitinib in patients with relapsed or persistent ovarian or primary peritoneal carcinoma and evaluation of epidermal growth factor receptor mutations and immunohistochemical expression: a Gynecologic Oncology Group Study. Clin Cancer Res 2005, 11(15):5539-5548.
54. Posadas E.M., Liel M.S., Kwitkowski V., Minasian L., Godwin A.K., Hussain M.M., et al. A phase II and pharmacodynamic study of gefitinib in patients with refractory or recurrent epithelial ovarian cancer. Cancer 2007, 109(7):1323-1330.
55. Wagner U., du Bois A., Pfisterer J., Huober J., Loibl S., Luck H.J., et al. Gefitinib in combination with tamoxifen in patients with ovarian cancer refractory or resistant to platinum-taxane based therapy - a phase II trial of the AGO Ovarian Cancer Study Group (AGO-OVAR 2.6). Gynecol Oncol 2007, 105(1):132-137.
56. Pautier P., Joly F., Kerbrat P., Bougnoux P., Fumoleau P., Petit T., et al. Phase II study of gefitinib in combination with paclitaxel (P) and carboplatin (C) as second-line therapy for ovarian, tubal or peritoneal adenocarcinoma (1839IL/0074). Gynecol Oncol 2010, 116(2):157-162.
57. Clynes R.A., Towers T.L., Presta L.G., Ravetch J.V. Inhibitory Fc receptors modulate in vivo cytotoxicity against tumor targets. Nat Med 2000, 6(4):443-446.
58. Cohen R.B. Epidermal growth factor as a therapeutic target in colorectal cancer. Clin Colorectal Cancer 2003, 2(4):246-251.
59. Dicker A.P., Rodeck U. Targeting the EGFR in neoplasia - more questions than answers. Int J Radiat Oncol Biol Phys 2004, 58(3):899-902.
60. Stordal B., Pavlakis N., Davey R. A systematic review of platinum and taxane resistance from bench to clinic: an inverse relationship. Cancer Treat Rev 2007, 33(8):688-703.
61. Morgillo F., Lee H.Y. Resistance to epidermal growth factor receptor-targeted therapy. Drug Resist Update 2005, 8(5):298-310.
62. Cappuzzo F., Hirsch F.R., Rossi E., Bartolini S., Ceresoli G.L., Bemis L., et al. Epidermal growth factor receptor gene and protein and gefitinb sensitivity in non-small-cell lung cancer. J Natl Cancer Inst 2005, 97(9):643-655.
63. Hirsch F.R., Varella-Garcia M., McCoy J., West H., Xavier A.C., Gumerlock P., et al. Increased epidermal growth factor receptor gene copy number detected by fluorescence in situ hybridization associates with increased sensitivity to gefitinib in patients with bronchioloalveoloar carcinoma subtypes: a Southwest Oncology Group Study. J Clin Oncol 2005, 23(28):6838-6845.
64. Han S.W., Hwang P.G., Chung D.H., Kim D.W., Im S.A., Kim Y.T., et al. Epidermal growth factor receptor (EGFR) downstream molecules as response predictive markers for gefitinib (Iressa, ZD 1839) in chemotherapy-resistance cell lung cancer. Int J Cancer 2005, 113(1):109-115.
65. Chung K.Y., Shia J., Kemeny N.E., Shah M., Schwartz G.K., Tse A., et al. Cetuximab shows activity in colorectal cancer patients with tumors that do not express the epidermal growth factor receptor by immunohistochemistry. J Clin Oncol 2005, 23(9):1803-1810.
66. Liu B., Fang M., Lu Y., Mendelsohn J., Fan Z. Fibroblast growth factor and insulin-like growth factor differentially modulate the apoptosis and G1 arrest induced by anti-epidermal growth factor receptor monoclonal antibody. Oncogene 2001, 20(15):1913-1922.
67. Wakeling A.E., Guy S.P., Woodburn J.R., Ashton S.E., Curry B.J., Barker A.J., et al. ZD1839 (Irassa): an orally active inhibitor of epidermal growth factor signaling with potential for cancer therapy. Cancer Res 2002, 62(20):5749-5754.
68. Learn C.A., Hartzell T.L., Wikstrand C.J., Archer G.E., Rich J.N., Friedman A.H., et al. Resistance to tyrosine kinase inhibition by mutant epidermal growth factor receptor variant III contributes to the neoplastic phenotype of glioblastoma multiforme. Clin Cancer Res 2004, 10(9):3216-3224.
69. Paez J.G., Janne P.A., Lee J.C., Tracy S., Greulich H., Gabriel S., et al. EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy. Science 2004, 304(5676):1497-1500.
70. Amann J., Kalyankrishna S., Massion P.P., Ohm J.E., Girard L., Shigematsu H., et al. Aberrant epidermal growth factor receptor signaling and enhanced sensitivity of EGFR inhibitors in lung cancer. Cancer Res 2005, 65(1):226-235.
71. Campiglio M., Ali S., Knyazev P.G., Ullrich A. Characteristics of EGFR family-mediated HRG signals in human ovarian cancer. J Cell Biochem 1999, 73(4):522-532.
72. Koizumi F., Shimoyama T., Taquchi F., Saijo N., Nishio K. Establishment of a human non-small cell lung cancer line resistant to gefitinib. Int J Cancer 2005, 116(1):36-44.
73. Bianco R., Shin I., Ritter C.A., Yakes F.M., Basso A., Rosen N., et al. Loss of PTEN/MMAC1/TEP in EGF receptor-expressing tumor cells counteracts the antitumor action of EGFR tyrosine kinase inhibitors. Oncogene 2003, 22(18):2812-2822.
74. Massarelli E., Varella-Garcia M., Tang X., Xavier A.C., Ozburn N.C., Liu D.D., et al. KRAS mutation is an important predictor of resistance with epidermal growth factor receptor tyrosine kinase inhibitors in non-small-cell lung cancer. Clin Cancer Res 2007, 13(10):2890-2896.
75. Lievre A., Bachet J.B., Le Corre D., Boige V., Landi B., Emile J.F., et al. KRAS mutation status is predictive of response to cetuximab therapy in colorectal cancer. Cancer Res 2006, 66(8):3992-3995.
76. Miller V.A., Riely G.J., Zakowski M.F., Li A.R., Patel J.D., Heelan R.T., et al. Molecular characteristics of bronchioloalveolar carcinoma and adenocarcinoma, bronchioloalveolar carcinoma subtype, predict response to erlotinib. J Clin Oncol 2008, 26(9):1472-1478.
77. Auner V., Kriegshauser G., Tong D., Horvat R., Reinthaller A., Mustea A., et al. KRAS mutation analysis in ovarian samples using a high sensitivity biochip assay. BMC Cancer 2009, 9:111.
78. Jones H.E., Goddard L., Gee J.M., Hiscox S., Rubini M., Barrow D., et al. Insulin-like growth factor-I receptor signaling and acquired resistance to gefitib (ZD1839; Iressa) in human breast and prostate cancer cells. Endocr Relat Cancer 2004, 11(4):793-814.
79. Chakravarti A., Loeffler J.S., Dyson N.J. Insulin-like growth factor receptor I mediates resistance to anti-epidermal growth factor receptor therapy in primary human glioblastoma cells through continued activation of phosphoinositide 3-kinase signaling. Cancer Res 2002, 62(1):200-207.
80. Gschwind A., Zwick E., Prenzel N., Leserer M., Ullrich A. Cell communication networks: epidermal growth factor receptor transactivation as the paradigm for interreceptor signal transmission. Oncogene 2001, 20(13):1594-1600.
81. Marinissen M.J., Gutkind J.S. G-protein-coupled receptors and signaling networks: emerging paradigms. Trends Pharmacol Sci 2001, 22(7):368-376.
82. Krysan K., Lee J.M., Dohadwala M., Gardner B.K., Reckamp K.L., Garon E., et al. Inflammation, epithelial to mesenchymal transition, and epidermal growth factor receptor tyrosine kinase inhibitor resistance. J Thorac Oncol 2008, 3(2):107-110.